Earlier this month, based on interim phase 3 data, Bharat Biotech had reported a 81% efficacy for Covaxin. Data from a follow-up to the phase I trials of Bharat Biotech’s Covaxin shows that the immune response to the vaccine generated neutralising antibodies that remained elevated even three months after the receipt of the second dose. … Read more
“My deep appreciation to all the volunteers for reposing trust and expressing Pro Vaccine Public Health Volunteerism in Phase 3 clinical Trial of India’s first fully indigenous Covid-19 vaccine. Thank You India,” Suchitra Ella, Joint Managing Director, Bharat Biotech International Limited said. Bharat Biotech has successfully completed the enrolment of 25,800 volunteers for Phase 3 … Read more
Covaxin news, update: On January 3, the Ministry of Health and Family Welfare announced that Emergency Use Authorization (EUA) has been granted to Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin. With approvals of two Covid-19 vaccines—Covaxin (Bharat Biotech) and Covishield (Serum Institute-Oxford), India is all set to begin one of the world’s biggest … Read more
Anil Vij also tweeted that he has offered to become the first volunteer to be vaccinated for the same. Coronavirus Covid-19 vaccine Covaxin Phase 3 trial in India: Haryana Health Minister Anil Vij has offered himself as the “first volunteer” for the Phase 3 human trials of India’s first indigenous Coronavirus Vaccine candidate Covaxin. Vij … Read more